Generate Biomedicines Cash Flow Statement
NASDAQ: GENBHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Generate Biomedicines has no annual cash flow statement on file yet, so quarterly figures are shown instead.
Generate Biomedicines free cash flow
In the quarter ended Jun 30, 2026, Generate Biomedicines generated -$57.9 million of operating cash flow and spent $933,000 on capital expenditures. That left free cash flow of -$58.9 million, a free-cash-flow margin of -932.5% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Generate Biomedicines cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -67.25M | -61.71M | -56.74M | -44.31M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 3.20M | 3.27M | 3.30M | 3.41M |
| Stock-Based Compensation | 8.24M | 6.39M | 5.49M | 4.74M |
| Change in Working Capital | -8.42M | -22.47M | -912.00K | -14.51M |
| Operating Cash Flow | -57.94M | -80.39M | -48.75M | -53.18M |
| Capital Expenditures | -933.00K | -3.78M | -154.00K | -751.00K |
| Investing Cash Flow | 33.31M | -259.93M | -17.07M | 75.53M |
| Financing Cash Flow | -579.00K | 378.89M | -263.00K | 20.56M |
| Net Change in Cash | -25.21M | 38.57M | -66.08M | 42.92M |
| Free Cash Flow | -58.88M | -84.17M | -48.91M | -53.93M |
This table shows 4 quarterly periods of Generate Biomedicines's cash flow statement, from Q2 2026 back to Q? 2025, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow GENB's reporting calendar. What is a cash flow statement?